Convalescent Plasma (CCP) Program
You may have seen the recent news regarding the FDA “delaying” the blood plasma treatment for COVID-19. The context of the FDA announcement is regarding criteria and discussion surrounding emergency use authorizations (EUA) and does not affect the current usage or accessibility of CCP in to treat COVID-19 hospital patients. The use of convalescent plasma continues to remain available to patients through the national expanded access protocol and/or the emergency investigational new drug request.
The FDA announcement has not changed our CCP program and/or your ability to access these products. LifeServe Blood Center’s Convalescent Plasma program continues to grow as more individuals recover from COVID-19 and are able to donate CCP. Since April, we have distributed nearly 1,000 CCP doses to our regional hospitals and shared over 500 hundred doses nationally.
The CCP product remains available through Mayo’s Expanded Access Protocol (EAP) and we will continue to have this lifesaving plasma readily available when your hospital needs it to aid in the treatment and recovery of critically ill COVID-19 patients.